New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2013
09:37 EDTADX, PEOAdams Express, Petroleum & Resources name Mark Stoeckle As CEO
The Boards of Directors of The Adams Express Company (ADX) and Petroleum & Resources Corporation (PEO) named Mark Stoeckle as Chief Executive Officer for the Funds, succeeding long-time CEO Douglas Ober, who previously announced plans to retire this year. Stoeckle comes to the Funds from the global investment management firm BNP Paribas Investment Partners, where he has served since 2004 as Chief Investment Officer, U.S. Equities and Global Sector Funds.
News For ADX;PEO From The Last 14 Days
Check below for free stories on ADX;PEO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
05:25 EDTADXAdams Express, MedImmune announce clinical trial partnership
Advaxis (ADXS) has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The Phase I/II immunotherapy study will evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis' lead cancer immunotherapy vaccine, ADXS-HPV, as a treatment for patients with advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. Both MEDI4736 and ADXS-HPV are cancer immunotherapies, a new class of treatments that use the body's own immune system to help fight cancer. Under the terms of the agreement, MedImmune and Advaxis will evaluate the combination as a treatment for HPV-associated cervical cancer and squamous cell carcinoma of the head and neck. The Phase I part of the trial is expected to establish a recommended dose regimen of MEDI4736 with ADXS-HPV, and the Phase II portion will assess the safety and efficacy of the combination. The study will be funded and conducted by Advaxis. Results from the study will be used to determine whether further clinical development of this combination is warranted. Under the terms of the deal, MedImmune has a non-exclusive relationship with respect to HPV-driven tumour types. MedImmune has first right of negotiation for future development of combinations involving MEDI4736 and ADXS-HPV.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use